Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Trial ID or NCT#

NCT05103358

Status

not recruiting iconNOT RECRUITING

Purpose

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Official Title

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)
Minggui Pan, MD, PhD
Minggui Pan, MD, PhD
Medical oncologist, Sarcoma specialist
Clinical Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

Khadija Bedar
kbedar@stanford.edu

View on ClinicalTrials.gov